[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-ovarian-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,87,118,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100146180","phase-2-immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer-100146180",false,"NCT01174121","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab","* INCLUSION CRITERIA:\n* Measurable (per RECIST v1.0 criteria), metastatic cancer of one of the following types: upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian\u002Fendometrial, or endocrine tumors including neuroendocrine tumors. Patients must have at least one lesion that is resectable for TIL generation with minimal morbidity, preferentially using minimal invasive laparoscopic or thoracoscopic surgery for removal of superficial tumor deposit.\n* Confirmation of diagnosis of metastatic cancer by the NCI Laboratory of Pathology.\n* Refractory to approved standard systemic therapy. Specifically:\n\n  * Patients with metastatic colorectal cancer must have received oxaliplatin or irinotecan.\n  * Patients with hepatocellular carcinoma must have received sorafenib (Nexavar(R)), since level 1 data support a survival benefit with this agent.\n  * Patients with breast and ovarian cancer must be refractory to both first- and second-line treatments and must have received at least one second-line chemotherapy regimen.\n* Patients with 3 or fewer brain metastases that are \\\u003C 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1.\n* Patients of both sexes must be willing to practice birth control from the time of enrollment on this study and 12 months after the last dose of combined chemotherapy for individuals of child-bearing potential (IOCBP) and for four months after treatment for individuals that can father children.\n* IOCBP must have a negative pregnancy test be a pregnancy test prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nSerology\n\n* Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n\nHematology\n\n* ANC \\> 1000\u002Fmm\\^3 without the support of filgrastim\n* WBC greater than or equal to 2500\u002Fmm\\^3\n* Platelet count greater than or equal to 80,000\u002Fmm\\^3\n* Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n\nChemistry\n\n* Serum ALT\u002FAST less than or equal to 5.0 x ULN\n* Serum creatinine less than or equal to 1.5 x ULN\n* Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome, who must have a total bilirubin \\\u003C 3.0 mg\u002FdL.\n* Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to less than or equal to grade 1.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on protocol 03-C-0277.\n\nEXCLUSION CRITERIA:\n\n* Participants who are pregnant or nursing because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Advanced primary with impeding occlusion, perforation or bleeding, dependent on transfusion.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).\n* History of major organ autoimmune disease.\n* Grade 3 or 4 major organ irAEs clinically attributed to anti-PD-1\u002FPD-L1 therapy.\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immunecompetence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms.\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* Documented Child-Pugh score of B or C for hepatocellular carcinoma patients with known underlying liver dysfunction.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50%.\n* Patients who are receiving any other investigational agents.","ALL","18 Years","72 Years",{"count":20,"type":21},332,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nThe NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian\u002Fendometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells.\n\nObjective:\n\nThe purpose of this study is to see if these specifically selected tumor fighting cells can cause digestive tract, urothelial, breast, or ovarian\u002Fendometrial tumors to shrink and to see if this treatment is safe.\n\nEligibility:\n\n\\- Adults age 18-72 with upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian\u002Fendometrial cancer, or glioblastoma refractory to standard chemotherapy.\n\nDesign:\n\nWork up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed.\n\nSurgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product.\n\nLeukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. (Leukapheresis is a common procedure, which removes only the white blood cells from the patient.)\n\nTreatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment.\n\nFollow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days.\n\n...",[27,28,29,30,31],"Metastatic Colorectal Cancer","Metastatic Pancreatic Cancer","Metastatic Ovarian Cancer","Metastatic Breast Carcinoma","Metastatic Endocrine Tumors\u002F Neuroendocrine Tumors",[33,34,35,36,37],"Digestive Tract Cancers","Breast Cancer","Endocrine Tumors","Ovarian\u002FEndometrial Cancer","Genitourinary Cancer","RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-19","ACTUAL",{"date":44,"type":42},"2010-08-26",{"date":46,"type":21},"2029-12-27",{"name":48,"class":49},"National Cancer Institute (NCI)","NIH",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100650908","phase-1-study-to-assess-safety-tolerability-pharmacokinetics-immunogenicity-and-antitumor-activity-of-arr-002-in-advanced-or-metastatic-ovarian-or-endometrial-cancer-100650908","NCT07755436","Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.","A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.","Inclusion Criteria:\n\n* Patients with histologically and cytologically confirmed advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer, and platinum resistant who have failed or intolerant to standard therapy, or without alternative standard therapy.\n* Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n* Tumor specimen available for testing, or agree to biopsy at baseline.\n* The score of Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy ≥ 12 weeks.\n* Organ functions and coagulation function must meet the basic requirements.\n* Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n* Prior treatment with auristatin-derived drugs s (eg, MMAE and monomethyl auristatin F \\[MMAF\\]).\n* Received antitumor therapy within 4 weeks prior to the first dose or 5 half-lives, whichever is shorter.\n* Infection of active hepatitis B, active hepatitis C, or HIV.\n* Symptomatic Central nervous system and\u002For meninges metastasis.\n* History of uncontrolled diabetes mellitus or diabetic neuropathy within 3 months before the first dose of study treatment.\n* Previous drug-induced interstitial lung disease (ILD) or active ILD.\n* Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion.\n* History of recurrent gastrointestinal (GI) obstruction.\n* Patients with more than one cancer.\n* Any other diseases, pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding\n* Grade ≥ 2 peripheral neuropathy\n* History of severe cardiovascular diseases.\n* Current use of anticoagulants or thrombolytic agents for therapeutic purposes.\n* Known allergic reactions to any component of ARR-002.\n* Prior treatment with MUC16- or NaPi2b-targeting agents.\n* Ocular conditions such as keratitis or corneal ulceration, monocularity, corneal transplantation, uncontrolled retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder.\n* Other situations that are not suitable to participate a clinical trial per investigator's judgement.","FEMALE",{"count":60,"type":21},180,[62],"PHASE1","This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.",[65,66,67,29,68],"Ovarian Cancer","Endometrial Cancer","Platinum-resistant Ovarian Cancer (PROC)","Metastatic Endometrial Cancer",[70,71,72,73,29,66,74,75],"PROC","ARR-002","ARR002","Advanced Ovarian Cancer","Platinum-resistant Ovarian Cancer","antibody drug conjugates","2026-08-05",{"date":78,"type":42},"2026-08-10",{"date":80,"type":42},"2026-07-23",{"date":82,"type":21},"2029-05",{"name":84,"class":85},"ArriVent BioPharma, Inc.","INDUSTRY",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":50},"100648384","phase-2-sacituzumab-tirumotecan---pembrolizumab-in-io-exposed-metastatic-or-recurrent-ovarian-clear-cell-cancer-100648384","NCT07718854","Sacituzumab Tirumotecan +\u002F- Pembrolizumab in I\u002FO Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","A Phase 2 Randomized Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy","Inclusion Criteria:\n\nType of Participant and Disease Characteristics\n\n1. Has a histologically-confirmed diagnosis of pure OCCC. Patients with mixed histologies that include a clear cell component will not be eligible for this trial.\n2. Has measurable disease per RECIST 1.1 as assessed by the local site investigator\u002F radiology. Lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions.\n3. Patients must have received at least one prior platinum and taxane based chemotherapy regimen. Radiation therapy (including the use of chemotherapy as a radiosensitizer) will not count as a prior systemic regimen.\n4. Patients must have also received one prior line containing an immune checkpoint inhibitor (ICI) More than one prior line of ICI treatment will be exclusionary.\n5. Participants with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n6. ECOG performance status 0-1\n7. Is an individual of assigned female sex at birth and is at least 18 years of age at the time of providing the informed consent.\n8. Participant is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n   * Is not a Person of Child-Bearing Potential (POCBP) OR\n   * Is a POCBP and:\n\n     \\- Agrees to use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 5 during the intervention period and for at least the time needed to eliminate the study intervention after the last dose of study intervention. The participant agrees not to donate eggs (ova, oocytes) to others or freeze\u002Fstore eggs during this period for the purpose of reproduction. The length of time required to continue contraception for Sacituzumab tirumotecan is 210 days.\n\n     ◦ sacituzumab tirumotecan: 210 days\n\n     \\- The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by POCBPs should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.\n     * Has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Additional requirements for pregnancy testing during and after study intervention are in Section 8.3.5.\n     * Abstains from breastfeeding during the study intervention period and for at least 10 days after study intervention.\n     * Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.\n\nInformed Consent 8. The participant (or legally acceptable representative if applicable) provides written informed consent for the study.\n\nAdditional Categories 9. Has provided an archival tumor tissue sample (slides or block) for pathologic confirmation of diagnosis at Tufts Medical Center.\n\n10\\. Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except for alopecia and vitiligo). Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible.\n\n11\\. Adequate organ function as defined in the following table (Table 3). Specimens must be collected within 10 days before the start of study intervention.\n\n12\\. Any other medical condition that will prevent the safe administration of study drugs in the opinion of the treating physician.\n\n13\\. Be willing and able to comply with study procedures, laboratory tests, and other requirements of the study.\n\n14\\. HIV-infected participants must have well-controlled HIV on ART, defined as:\n\n1. Having a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening\n2. Having achieved and maintained virologic suppression, defined as confirmed HIV RNA level below 50 or the LLOQ using the locally available assay, at the time of screening and for at least 12 weeks before screening.\n3. Absence of any AIDS-defining opportunistic infections within the past 12 months\n4. Being on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before randomization and agreeing to continue ART throughout the study Note: The ART regimen must not contain any antiretroviral medications that are strong CYP3A4 inducers\u002Finhibitors\u002Fsubstrates. Refer to https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer\u002Finhibitor\u002Fsubstrate of CYP3A4.\n\nHIV testing at screening is not otherwise required. 15. Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization.\n\nNote: Participants should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.\n\nHepatitis B testing at screening is not required unless:\n\n* There is a known history of HBV infection\n* Mandated by local guidelines 16. Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\nNote: Participants must have completed curative antiviral therapy at least 4 weeks before randomization.\n\nHepatitis C testing at screening is not required unless:\n\n* There is a known history of HCV infection\n* Mandated by local guidelines\n\nExclusion Criteria:\n\nMedical Conditions\n\n1. Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing.\n2. Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and\u002For other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention.\n3. Is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n4. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid)\n5. History of stem cell\u002Fsolid organ transplant. Prior\u002FConcomitant Therapy\n6. Received prior treatment with a TROP2-targeted ADC.\n7. Received prior treatment with a topoisomerase 1 inhibitor-containing ADC.\n8. Received prior systemic anticancer therapy within 2 weeks before the first dose of study intervention.\n9. Received prior radiotherapy within 2 weeks before the first dose of study intervention, has radiation-related toxicities, requiring corticosteroids, and\u002For has radiation pneumonitis.\n\n   Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.\n10. Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n\n    Refer to Section 6.2 for information on COVID-19 vaccines.\n11. Is currently receiving a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks.\n\n    Note: A list of strong inducers\u002Finhibitors of CYP3A4 can be found at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer\u002Finhibitor of CYP3A4.\n\n    Prior\u002FConcurrent Clinical Study Experience\n12. Is currently enrolled on another therapeutic clinical trial. Concurrent enrollment on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy is prohibited.\n13. Has received an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.\n\n    Diagnostic Assessments\n14. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of any organ (excluding carcinoma in situ of the bladder) who have undergone potentially curative resection are not excluded.\n\n    Note: Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \\\u003C10 ng\u002FmL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.\n15. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously-treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during study screening, are clinically stable, and have not required steroid treatment for at least 14 days before the first dose of study intervention.\n16. Has an active infection requiring systemic therapy.\n17. Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the treating investigator.\n\n    Other Exclusions\n18. Severe hypersensitivity (Grades ≥3) to study interventions, any of their excipients, and\u002For to another biologic therapy.\n19. Has had major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary.\n\n    Note: Participants who underwent major surgery must have adequately recovered from toxicity and\u002For complications from the surgery before starting study intervention.\n20. Has a history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n21. History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":95,"type":21},50,[24],"This is a phase II randomized study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, administered alone or in combination with pembrolizumab, a monoclonal antibody to PD-1 in patients with relapsed clear cell cancers that originated in the ovary, fallopian tube or peritoneal cavity, inclusive of endometriosis (collectively referred to as OCCC throughout the protocol) after previous treatment with anti-PD1 therapy.",[99,29,100],"Ovarian Clear Cell Carcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma",[102,103,104,105,106],"clear cell carcinoma","ovarian","Sacituzumab","MK2870","pembrolizumab","NOT_YET_RECRUITING","2026-07-17",{"date":110,"type":42},"2026-07-22",{"date":112,"type":21},"2026-06",{"date":114,"type":21},"2032-03",{"name":116,"class":117},"Tufts Medical Center","OTHER",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":5},"100557070","phase-1-a-phase-1-trial-of-erx-315-in-participants-with-advanced-solid-tumors-100557070","NCT06533332","A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors","A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Patients must be at least 18 years of age at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and\u002For metastatic disease for whom standard therapies do not exist or are no longer effective\n* Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Adequate baseline organ function and hematologic function\n* Life expectancy \\>3 months\n\nExclusion Criteria:\n\n* Systemic anti cancer therapy within 4 weeks of first dose of study drug\n* Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.\n* Uncontrolled intercurrent illnesses\n* Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.",{"count":126,"type":21},36,[62],"This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.",[130,131,29,68,132,28],"Advanced Solid Tumor","Metastatic Breast Cancer","Metastatic Liver Cancer","2026-05-27",{"date":135,"type":42},"2026-05-29",{"date":137,"type":42},"2024-10-14",{"date":139,"type":21},"2027-06-30",{"name":141,"class":117},"EtiraRx Australia Pty Ltd",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":50},"100500493","phase-3-measuring-oncological-value-of-exercise-and-statin-100500493","NCT05796973","Measuring Oncological Value of Exercise and Statin","Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin","MOVES","Inclusion Criteria:\n\n* The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started\n* Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer.\n* Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.\n* Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and\u002For IO monotherapy or as a combination therapy.\n* Ovarian cancer: stage III or IV cancer for which chemotherapy treatment is started.\n* The patient agrees to the study and signs a written informed consent.\n* Adult (18 years=\\>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study.\n* In women, the use of a reliable contraceptive during the intervention\n\nExclusion Criteria:\n\n* High risk of bone fractures\n* Inability to physical exertion and\u002For unsuitability for cancer drug treatment\n* Poor co-operation ability for psychological reasons\n* Active use of cholesterol-lowering drugs\n* Severe liver or kidney failure\n* Troublesome side effects that occurred in the past during cholesterol medication\n* Continuous use of medicinal substances that interact with atorvastatin during the study period\n* A special group of subjects according to the EU Clinical Trials Regulation 536\u002F2014 (e.g. pregnant or lactating women)\n\nExclusion criteria in patients who are already using statin medication before the study:\n\n* High risk of bone fractures\n* Inability to physical exertion and\u002For unsuitability for cancer drug treatment\n* Poor co-operation ability for psychological reasons\n* Severe liver or kidney failure\n* A special group of subjects according to the EU Clinical Trials Regulation 536\u002F2014 (e.g. pregnant or lactating women)","99 Years",{"count":152,"type":21},240,[154],"PHASE3","The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.",[157,34,158,65,131,159,160,161,162,163,29,164],"Prostate Cancer","Kidney Cancer","Metastatic Kidney Cancer","Metastatic Renal Cell Carcinoma","Metastatic Renal Cancer","Metastatic Prostate Cancer","Metastatic Prostate Adenocarcinoma","Metastatic Ovary Cancer","2025-06-23",{"date":167,"type":42},"2025-06-27",{"date":169,"type":42},"2023-03-31",{"date":171,"type":21},"2027-12-31",{"name":173,"class":117},"Tampere University Hospital"]